The Effects of the Dietary Approaches to Stop Hypertension (Dash) Diet on Oxidative Stress and Clinical Indices of Migraine Patients: A Randomized Controlled Trial Publisher Pubmed

Summary: DASH diet reduces NO, TOS, & migraine severity in women, suggesting a complementary treatment role. #DASHDiet #Migraine

Arab A¹ ; Khorvash F² ; Karimi E^{3, 4} ; Heidari Z⁵ ; Askari G¹
Source: Nutritional Neuroscience Published:2022

Abstract

Aims: The relationship between the Dietary Approaches to Stop Hypertension (DASH) diet and oxidative stress (OS) in patients diagnosed with migraine is unknown and remains to be examined. Hence, we conducted a parallel-group, randomized controlled trial to investigate this issue. Methods: Of the 102 women who met all the inclusion criteria, 51 individuals were randomized to the DASH diet group and 51 to the usual dietary advice group to receive allocated intervention for three months. In order to assess the compliance of participants to the DASH diet, dietary records, and serum vitamin C levels were examined. Parameters of OS status (e.g. nitric oxide (NO), total antioxidant capacity (TAC), total oxidative status (TOS), malondialdehyde (MDA), and oxidative stress index (OSI)) and clinical indices of migraine (e.g. migraine index (MI), headache dairy result (HDR), and migraine headache index score (MHIS)) were assessed at the beginning and the end of the study. Results: There was a significant reduction in NO (–5.75 vs. + 4.18, P = 0.025) and TOS (–1.55 vs. + 0.71, P = 0.034), and a marginally significant reduction in OSI (-0.10 vs. + 0.14, P = 0.060) in the DASH group compared with the control. Compliance with the DASH diet resulted in a significant decrease in the score of MI (–31.33 vs.–15.09), HDR (–5.04 vs. –2.51), and MHIS (–44.21 vs. –26.74). Moreover, no significant change was observed in TAC, MDA, and total thiol content. Conclusion: This type of dietary approach can be considered as a complementary treatment for migraine patients, also further investigations are needed to replicate our findings. Trial registration:Iranian Registry of Clinical Trials identifier: IRCT20121216011763N38. © 2021 Informa UK Limited, trading as Taylor & Francis Group.